229 related articles for article (PubMed ID: 27438145)
1. Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.
Ghelli Luserna Di Rorà A; Iacobucci I; Imbrogno E; Papayannidis C; Derenzini E; Ferrari A; Guadagnuolo V; Robustelli V; Parisi S; Sartor C; Abbenante MC; Paolini S; Martinelli G
Oncotarget; 2016 Aug; 7(33):53377-53391. PubMed ID: 27438145
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.
Iacobucci I; Di Rorà AG; Falzacappa MV; Agostinelli C; Derenzini E; Ferrari A; Papayannidis C; Lonetti A; Righi S; Imbrogno E; Pomella S; Venturi C; Guadagnuolo V; Cattina F; Ottaviani E; Abbenante MC; Vitale A; Elia L; Russo D; Zinzani PL; Pileri S; Pelicci PG; Martinelli G
J Hematol Oncol; 2015 Nov; 8():125. PubMed ID: 26542114
[TBL] [Abstract][Full Text] [Related]
3. Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development.
Angius G; Tomao S; Stati V; Vici P; Bianco V; Tomao F
Cancer Chemother Pharmacol; 2020 Jan; 85(1):9-20. PubMed ID: 31512029
[TBL] [Abstract][Full Text] [Related]
4. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Lowery CD; Dowless M; Renschler M; Blosser W; VanWye AB; Stephens JR; Iversen PW; Lin AB; Beckmann RP; Krytska K; Cole KA; Maris JM; Hawkins DS; Rubin BP; Kurmasheva RT; Houghton PJ; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Erickson SW; Teicher BA; Smith MA; Stancato LF
Clin Cancer Res; 2019 Apr; 25(7):2278-2289. PubMed ID: 30563935
[TBL] [Abstract][Full Text] [Related]
5. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
Zeng L; Nikolaev A; Xing C; Della Manna DL; Yang ES
Mol Cancer Ther; 2020 Jun; 19(6):1279-1288. PubMed ID: 32371584
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Cho HY; Kim YB; Park WH; No JH
Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
[TBL] [Abstract][Full Text] [Related]
7. The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.
Lowery CD; VanWye AB; Dowless M; Blosser W; Falcon BL; Stewart J; Stephens J; Beckmann RP; Bence Lin A; Stancato LF
Clin Cancer Res; 2017 Aug; 23(15):4354-4363. PubMed ID: 28270495
[No Abstract] [Full Text] [Related]
8. Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib.
Heidler CL; Roth EK; Thiemann M; Blattmann C; Perez RL; Huber PE; Kovac M; Amthor B; Neu-Yilik G; Kulozik AE
Int J Cancer; 2020 Aug; 147(4):1059-1070. PubMed ID: 31782150
[TBL] [Abstract][Full Text] [Related]
9. CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model.
Campagne O; Davis A; Maharaj AR; Zhong B; Stripay J; Farmer D; Roussel MF; Stewart CF
Eur J Pharm Sci; 2020 Jan; 142():105106. PubMed ID: 31669383
[TBL] [Abstract][Full Text] [Related]
10. Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.
Ostergaard J; Jonart LM; Ebadi M; Koppenhafer SL; Gordon DJ; Gordon PM
Br J Haematol; 2021 Sep; 194(6):1094-1098. PubMed ID: 34096630
[TBL] [Abstract][Full Text] [Related]
11. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
Ghelli Luserna Di Rorà A; Ghetti M; Ledda L; Ferrari A; Bocconcelli M; Padella A; Napolitano R; Fontana MC; Liverani C; Imbrogno E; Bochicchio MT; Paganelli M; Robustelli V; Sanogo S; Cerchione C; Fumagalli M; Rondoni M; Imovilli A; Musuraca G; Martinelli G; Simonetti G
Cell Biol Toxicol; 2023 Jun; 39(3):795-811. PubMed ID: 34519926
[TBL] [Abstract][Full Text] [Related]
12. Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma.
Chaudhary R; Slebos RJC; Song F; McCleary-Sharpe KP; Masannat J; Tan AC; Wang X; Amaladas N; Wu W; Hall GE; Conejo-Garcia JR; Hernandez-Prera JC; Chung CH
Mol Carcinog; 2021 Feb; 60(2):138-150. PubMed ID: 33378592
[TBL] [Abstract][Full Text] [Related]
13. Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances
Zeng L; Beggs RR; Cooper TS; Weaver AN; Yang ES
Mol Cancer Ther; 2017 Apr; 16(4):591-600. PubMed ID: 28138028
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Cash T; Fox E; Liu X; Minard CG; Reid JM; Scheck AC; Weigel BJ; Wetmore C
Pediatr Blood Cancer; 2021 Sep; 68(9):e29065. PubMed ID: 33881209
[TBL] [Abstract][Full Text] [Related]
15. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
[TBL] [Abstract][Full Text] [Related]
16. Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.
Ghelli Luserna Di Rorà A; Beeharry N; Imbrogno E; Ferrari A; Robustelli V; Righi S; Sabattini E; Verga Falzacappa MV; Ronchini C; Testoni N; Baldazzi C; Papayannidis C; Abbenante MC; Marconi G; Paolini S; Parisi S; Sartor C; Fontana MC; De Matteis S; Iacobucci I; Pelicci PG; Cavo M; Yen TJ; Martinelli G
J Hematol Oncol; 2018 Aug; 11(1):99. PubMed ID: 30068368
[TBL] [Abstract][Full Text] [Related]
17. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
[TBL] [Abstract][Full Text] [Related]
18. Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation.
Zhao X; Kim IK; Kallakury B; Chahine JJ; Iwama E; Pierobon M; Petricoin E; McCutcheon JN; Zhang YW; Umemura S; Chen V; Wang C; Giaccone G
Mol Oncol; 2021 Apr; 15(4):1130-1145. PubMed ID: 33320980
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
